Literature DB >> 4080121

Late epilepsy after aneurysm operations.

T Keränen, A Tapaninaho, J Hernesniemi, M Vapalahti.   

Abstract

The risk of late epilepsy was analyzed in a consecutive series of 177 patients operated on for supratentorial aneurysms. Late seizures occurred in 25 patients (14%); the seizures were recurrent in 21 patients (12%). Most seizures were partial, secondary generalized, or generalized tonic-clonic (72%). The mean latency between the operation and seizures was 8.4 months (range, 1 to 24 months), and in only 2 patients was the interval more than 12 months. The most important risk factors were preoperative and postoperative complications. Only 2.5% of the 81 Grade I patients developed epilepsy, compared to 33% of the 42 Grade III-IV patients. Other risk factors were location of the aneurysm in the middle cerebral artery, the presence of a large intracerebral hematoma, postoperative spasm with late ischemic infarction, and shunt-dependent hydrocephalus. The timing of operation or intraventricular intracranial pressure monitoring did not change the risk of late epilepsy. The fact that only 2 patients had early epilepsy may have been due to routine treatment with prophylactic anticonvulsants. The value of prophylaxis in late epilepsy is unproven, but prophylactic treatment could be useful in patients with a high risk of epileptic seizures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4080121     DOI: 10.1227/00006123-198512000-00004

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

1.  Levetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhage.

Authors:  Scott Taylor; Robin J Heinrichs; Jeff M Janzen; As'ad Ehtisham
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 2.  Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage.

Authors:  Giuseppe Lanzino; Pietro Ivo D'Urso; Jose Suarez
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

3.  Risk factors for developing epilepsy after craniotomy in children.

Authors:  Dimitris Kombogiorgas; N Shastri Jatavallabhula; Spyros Sgouros; Vivek Josan; A Richard Walsh; Anthony D Hockley
Journal:  Childs Nerv Syst       Date:  2006-05-30       Impact factor: 1.475

4.  Epilepsy after operative treatment of ruptured cerebral aneurysms.

Authors:  V Ukkola; E R Heikkinen
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

5.  Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects.

Authors:  L F Beenen; J Lindeboom; D G Kasteleijn-Nolst Trenité; J J Heimans; F J Snoek; D J Touw; H J Adèr; H A van Alphen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-10       Impact factor: 10.154

6.  Seizures and Epilepsy following Aneurysmal Subarachnoid Hemorrhage : Incidence and Risk Factors.

Authors:  Kyu-Sun Choi; Hyoung-Joon Chun; Hyeong-Joong Yi; Yong Ko; Young-Soo Kim; Jae-Min Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-08-31

7.  High risk for seizures following subarachnoid hemorrhage regardless of referral bias.

Authors:  Kathryn L O'Connor; M Brandon Westover; Michael T Phillips; Nicolae A Iftimia; Deidre A Buckley; Christopher S Ogilvy; Mouhsin M Shafi; Eric S Rosenthal
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

8.  Risk of epilepsy after aneurysm operations.

Authors:  J Bidziński; A Marchel; A Sherif
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

9.  Emergency treatment of cerebral aneurysms with large haematomas.

Authors:  A Tapaninaho; J Hernesniemi; M Vapalahti
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

Review 10.  Use of prophylactic anticonvulsants in neurologic critical care: a critical appraisal.

Authors:  Kenneth C Liu; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.